(NP (NP-COOD (NP (NP Estrogen/NN binding/NN sites/NNS) (PP in/IN (NP peripheral/JJ blood/NN monocytes/NNS))) and/CC (NP (NP effects/NNS) (PP of/IN (NP danazol/NN)) (PP on/IN (NP (NP their/PRP$ sites/NNS) (ADVP in/FW vitro/FW))))) ./.)
(S (LST 1/LS ./.) (NP-SBJ-29 This/DT study/NN) (VP was/VBD (VP designed/VBN (NP-30 *-29/-NONE-) (S (NP-SBJ *-30/-NONE-) (VP to/TO (VP investigate/VB (NP-COOD (NP (NP the/DT presence/NN) (PP of/IN (NP estrogen/NN (NP-COOD (NP (NP type/NN I/CD) (PRN -LRB-/-LRB- (FRAG (NP-COOD (NP high/JJ affinity/NN) ,/, (NP low/JJ capacity/NN))) -RRB-/-RRB-)) and/CC (NP (NP type/NN II/CD) (PRN -LRB-/-LRB- (FRAG (NP-COOD (NP low/JJ affinity/NN) ,/, (NP high/JJ capacity/NN))) -RRB-/-RRB-))) binding/NN sites/NNS)) (PP in/IN (NP human/JJ peripheral/JJ blood/NN monocytes/NNS))) and/CC (NP (NP the/DT effects/NNS) (PP of/IN (NP danazol/NN)) (PP on/IN (NP these/DT sites/NNS))))))))) ./.)
(S (LST 2/LS ./.) (NP-SBJ (NP These/DT two/CD types/NNS) (PP of/IN (NP estrogen/NN binding/NN sites/NNS))) (VP existed/VBD (PP in/IN (NP human/JJ peripheral/JJ blood/NN monocytes/NNS))) ./.)
(S (LST 3/LS ./.) (NP-SBJ Danazol/NN) (VP-COOD (VP bound/VBD (PP to/TO (NP these/DT sites/NNS)) (PP in/IN (NP (NP high/JJ concentration/NN) (PRN -LRB-/-LRB- (NP (NP (UCP-COOD (NP 10-LRB--6-RRB-/CD M/NN) ,/, (ADJP clinical/JJ)) serum/NN concentration/NN) (PP-TMP during/IN (NP danazol/NN therapy/NN))) -RRB-/-RRB-)))) and/CC (VP decreased/VBD (NP (NP the/DT number/NN) (PP of/IN (NP both/DT sites/NNS))))) ./.)
(S (LST 4/LS ./.) (NP-SBJ It/PRP) (VP is/VBZ (VP suggested/VBN (SBAR that/IN (S (NP-SBJ danazol/NN) (VP has/VBZ (NP (NP an/DT anti-estrogenic/JJ action/NN) (PP to/TO (NP the/DT monocytes/NNS))) (PP through/IN (NP (NP the/DT (NP-COOD (NP competition/NN) and/CC (NP suppression/NN))) (PP of/IN (NP estrogen/NN binding/NN sites/NNS)))) (SBAR as/IN (S (NP-SBJ-31 */-NONE-) (VP seen/VBN (NP *-31/-NONE-) (PP in/IN (NP the/DT estrogen/NN target/NN organ/NN)))))))))) ./.)
